Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2026-525923-26-00 | Registry Identifier | EUCT number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| JNJ-78934804 | Experimental | Participants will receive JNJ-78934804 induction dose at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind (DB) treatment phase (Week 48) and benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase. |
|
| Guselkumab | Active Comparator | Participants with moderately to severely active UC will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete DB treatment phase (Week 48) and benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the LTE phase. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| JNJ-78934804 | Drug | JNJ-78934804 will be administered subcutaneously. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants in Clinical Remission at Week 48 | Clinical remission is defined as an stool frequency (SF) subscore of 0 or 1, rectal bleeding (RB) subscore of 0, and an endoscopy subscore of 0 or 1. | At Week 48 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Endoscopic Improvement at Week 48 | Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. | At Week 48 |
| Percentage of Participants with Corticosteroid-free (90 day) Clinical Remission at Week 48 |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Study Contact | Contact | 844-434-4210 | Participate-In-This-Study1@its.jnj.com |
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinnova Research | Recruiting | Anaheim | California | 92805 | United States | |
| Gastro SB Clinic |
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Guselkumab | Drug | Guselkumab will be administered subcutaneously. |
|
|
Corticosteroid-free (90 day) clinical remission is defined as clinical remission at the visit and not receiving corticosteroids for 90 days prior to the visit.
| At Week 48 |
| Percentage of Participants Achieving a Combination of Histologic Remission and Endoscopic Improvement at Week 48 | Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Histologic remission is defined as an absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system. | At Week 48 |
| Percentage of Participants with Fatigue Response (PROMIS Fatigue Short Form 7a) at Week 48 | Fatigue response is defined as a greater than or equal to (>=) 7- point reduction in the patient-reported outcomes measurement information system (PROMIS) fatigue short form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise). | At Week 48 |
| Percentage of Participants with Sustained Mayo SF Less Than or Equal to (<=) 1 and RB=0 | Percentage of participants with a SF subscore of 0 or 1 and RB subscore of 0 at three assessment time points of Week 12, Week 24, and Week 48 will be reported. | At Weeks 12, 24, and 48 |
| Percentage of Participants in Abdominal Pain Remission at Week 48 | Percentage of participants in abdominal pain remission at week 48 will be reported. | At Week 48 |
| Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48 | IBDQ response is defined as improvement from baseline in the total IBDQ score of >= 16 points. The IBDQ is a 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific health-related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic functions (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). | At Week 48 |
| Percentage of Participants with PROMIS-29 Mental Component Summary (MCS) Response at Week 48 | PROMIS 29 MCS response is defined as a >= 7-point improvement from baseline in PROMIS 29 MCS response at Week 48. The PROMIS-29 is a collection of short forms containing 4 items for each of 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities). The PROMIS-29 MCS will be assessed, which is primarily informed by domains of emotional distress (depression/anxiety) and fatigue as well as sleep disturbance where higher MCS scores reflect better mental health. | At Week 48 |
| Percentage of Participants in Clinical Remission at Week 12 | Clinical remission is defined as an SF subscore of 0 or 1, RB subscore of 0, and an endoscopy subscore of 0 or 1. | At Week 12 |
| Percentage of Participants with Endoscopic Improvement at Week 12 | Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. | At Week 12 |
| Percentage of Participants with Mayo SF/RB Response at Week 2 | Mayo SF/RB response is defined as a decrease from baseline in the sum of the SF and the RB subscores by >=30 percent (%) and >= 1 point, with either a >= 1 point decrease from baseline in the RB subscore or an RB subscore of 0 or 1. | At Week 2 |
| Percentage of Participants with Adverse Events (AE) and Serious AEs (SAEs) | An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important. | Up to approximately 3 years |
| Recruiting |
| Chula Vista |
| California |
| 91910 |
| United States |
| Peak Gastroenterology Associates | Recruiting | Colorado Springs | Colorado | 80907 | United States |
| Sanchez Clinical Research, Inc | Recruiting | Miami | Florida | 33157-6575 | United States |
| GCP Clinical Research | Recruiting | Tampa | Florida | 33609 | United States |
| New York Gastroenterology Associates | Recruiting | New York | New York | 10075 | United States |
| Southern Star Research Institute, LLC | Recruiting | San Antonio | Texas | 78229 | United States |
| SA Gastrointestinal Services | Recruiting | Kurralta Park | 5037 | Australia |
| GI Research Institute (G.I.R.I.) | Recruiting | Vancouver | British Columbia | V6Z 2K5 | Canada |
| London Digestive Disease Institute | Recruiting | London | Ontario | N6K 1M6 | Canada |
| Rambam Medical Center | Recruiting | Haifa | 3109601 | Israel |
| Bnai Zion Medical Center | Recruiting | Haifa | 60910 | Israel |
| Meir Medical Center | Recruiting | Kfar Saba | 4428164 | Israel |
| Sheba Medical Center | Recruiting | Ramat Gan | 52621 | Israel |
| Tel Aviv Sourasky Medical Center | Recruiting | Tel Aviv | 64239 | Israel |
| Matsuda Hospital | Recruiting | Hamamatsu | 432-8061 | Japan |
| National Hospital Organization Mito Medical Center | Recruiting | Higashi-Ibaraki | 311-3193 | Japan |
| Kagoshima IBD Gastroenterology Clinic | Recruiting | Kagoshima | 892-0843 | Japan |
| Oita Red Cross Hospital | Recruiting | Ōita | 870-0033 | Japan |
| Saga University Hospital | Recruiting | Saga | 849-8501 | Japan |
| Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital | Recruiting | Sapporo | 060-0033 | Japan |
| Hospital Sultanah Nur Zahirah | Recruiting | Kuala Terengganu | 20400 | Malaysia |
| Sanko Universitesi Hastanesi | Recruiting | Gaziantep | 27090 | Turkey (Türkiye) |
| Bezmialem University Medical Faculty | Recruiting | Istanbul | 34093 | Turkey (Türkiye) |
| Kocaeli University Medical Faculty | Recruiting | Kocaeli | 41001 | Turkey (Türkiye) |
| Mersin University Medical Faculty | Recruiting | Mersin | 33343 | Turkey (Türkiye) |
| ID | Term |
|---|---|
| D003093 | Colitis, Ulcerative |
| ID | Term |
|---|---|
| D003092 | Colitis |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D015212 | Inflammatory Bowel Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000588857 | guselkumab |
Not provided
Not provided
Not provided